Pre-earnings options volume in Nuvation Bio (NUVB) is 2.1x normal with calls leading puts 13:1. Implied volatility suggests the market is anticipating a move near 19.2%, or 99c, after results are released. Median move over the past eight quarters is 2.1%.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVB:
- Is NUVB a Buy, Before Earnings?
- Nuvation Bio enrolls first patient in G203 study
- Optimistic Buy Rating for Nuvation Bio Driven by Promising Prospects of Ibtrozi and Safusidenib
- Nuvation Bio enrolls first patient in TRUST-IV Phase 3 study of IBTROZI
- Nuvation Bio’s Strategic Growth Potential and Promising Pipeline Justify Buy Rating